Increased platelet activity after termination of prostacyclin infusion into man. 1981

A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny

Infusion of PGI2 at a dose of 5 or 10 ng/kg/min during 72 hours into patients with peripheral vascular disease was followed by increased susceptibility of platelets to proaggregatory action of ADP and collagen but not that of arachidonate. The above effects were observed 24 hours after termination of infusion of PGI2. A tendency to an increased formation of TXA2 in PRP aggregated by arachidonate was also noticed. Infusion of PGI2 at a dose of 2 mg/kg/min during 72 hours into the patients caused the decreased platelet aggregability to ADP and arachidonate but not to collagen, and a decreased tendency to production of TXA2 in PRP aggregated by arachidonate. The existence of a "rebound effect" in platelets after a long term PGI2 therapy is suggested.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
August 1978, Thrombosis research,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
January 1980, Thrombosis research,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
October 2010, Circulation. Cardiovascular interventions,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
April 1984, Prostaglandins, leukotrienes, and medicine,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
July 1994, Prostaglandins,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
February 1980, Prostaglandins,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
May 1981, Experientia,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
September 1984, British journal of clinical pharmacology,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
December 1985, Circulation,
A Dembinska-Kiec, and A Zmuda, and L Grodzinska, and K Bieron, and M Basista, and A Kedzior, and E Kostka-Trabka, and E Telesz, and T Zelazny
December 1987, Thrombosis research,
Copied contents to your clipboard!